12 Best Low Risk High Growth Stocks to Invest In

8. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Number of Hedge Fund Holders: 49

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company that discovers, develops, and markets neurological drugs. In earnings for the third quarter, the company reported strong financial growth as net product sales of INGREZZA (valbenazine) totaled $613 million, underscoring a 26% year-over-year increase. This demonstrates effective marketing and solidifies INGREZZA as a key revenue driver, reinforcing its leadership in treating tardive dyskinesia. On January 28, the company launched a Phase 3 registrational study to assess the efficacy, safety, and tolerability of osavampator, an investigational drug being developed as an additional treatment to antidepressants for major depressive disorder (MDD). Eiry Roberts, a senior officer at Neurocrine Biosciences, has stated that osavampator has the potential to become a first-in-class treatment for MDD, a disorder affecting more than 21 million people in the United States.